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Objective: Rodent models of osteoarthritis and rheumatoid arthritis are useful tools to study these disease
processes. Adjuvant arthritis (AAR) is a model of polyarthritis widely used for preclinical testing of
antiarthritis substances. We report the effect of two different doses of highly puriﬁed chondroitin sulfate
(CS) pharmaceutical grade in the AAR animal model after oral administration.
Design: AAR was induced by a single intradermal injection of heat-inactivated Mycobacterium butyricum
in incomplete Freund’s adjuvant. The experiments included healthy animals, untreated arthritic animals,
arthritic animals having been administered 300 or 900 mg/kg of CS daily, 14 days before AAR induction
until the end of the experiment (day 28), arthritic animals having been administered 300 or 900 mg/kg of
CS daily, from day 1 until the end of the experiment.
Results: CS was capable of signiﬁcantly reducing the severity of arthritis along with oxidative stress,
a consequence of chronic inﬂammatory processes occurring in AAR. The CS pre-treatment regimen was
effective throughout the whole subacute phase, while treatment from day 1 proved effective only in the
chronic period. The effects were conﬁrmed by improved total antioxidant status and g-glutamyl-
transferase activity. CS administered under a pre-treatment regimen was also able to reduce the
production of pro-inﬂammatory cytokines, C-reactive protein in plasma, phagocytic activity and the
intracellular oxidative burst of neutrophils.
Conclusions: CS proved to be effective in slowing down AAR development and in reducing disease
markers, thus supporting its beneﬁcial activity as a drug in humans.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Chondroitin sulfate (CS) belongs to the class of natural complex
polysaccharides named glycosaminoglycans (GAGs) and is an
unbranched, polydisperse, complex macromolecule extracted and
puriﬁed from various tissues1e3. It is composed of alternate disac-
charide sequences of differently sulfated residues of D-glucuronic
acid (GlcA) and of N-acetyl-D-galactosamine (GalNAc)1e3. Depend-
ing on the disaccharide nature, CS types with different carbohy-
drate backbones are known. The sulfation heterogeneity is
responsible for a great variability in charge density as well as for the
presence of low- or highly-sulfated sequences inside the carbohy-
drate backbone. Furthermore, the number of disaccharide units
forming the CS polymer is another key factor inﬂuencing biological
and pharmacological activity. As a consequence, CS representsNicola Volpi, Department of
ampi 213/D, Modena 41100,
s Research Society International. Pa widely heterogeneous family of polysaccharides, in terms of
degree of sulfatation, molecular mass, relative amounts of GlcA and
iduronic acid, depending on the tissue of origin.
Symptomatic slow-acting drugs for the treatment of osteoar-
thritis (SYSADOA) are compounds which have been prescribed as
drugs in European countries for many years4. These compounds are
not rapidly acting agents, as are NonSteroidal Anti-Inﬂammatory
Drugs, and their clinical efﬁcacy can only be demonstrated after
a relatively long period of regular intake. However, once the
administration is terminated, they do show carry-over effects of
various durations, depending on the different formulations.
CS belongs to the oral SYSADOA substances having the power to
provide relief from pain and increased mobility in osteoarthritis
(OA) patients4. In fact, CS is currently recommended by the
European League Against Rheumatism (EULAR) as a SYSADOA in
Europe in the treatment of knee5, hip and hand6 OA. Finally, recent
clinical trials have demonstrated the possible structure-modifying
effects of CS7,8 as an additional very important factor to be consid-
ered with respect to its well-documented symptom-modifying
properties.ublished by Elsevier Ltd. All rights reserved.
Fig. 1. Schematic representation of the experimental model.
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to evaluate CS treatment in an effort to understand the molecular
basis of its efﬁcacy. For example, CS at increasing doses was orally
administered to mice once daily, beginning 14 days before initial
immunization in type II collagen-induced arthritis9. At the higher
dose (1000 mg/kg), CS signiﬁcantly inhibited hind paw edema,
synovitis and destruction of the articular cartilage. Comparable
results were observed in the same animal model by oral adminis-
tration of low-molecular-weight CS10 and CS puriﬁed from Raja
cartilage11. Furthermore, oral intake of CS was demonstrated to
inhibit the speciﬁc IgE production and antigen-induced anaphy-
lactic response by up-regulating regulatory T-cell differentiation,
followed by down-regulation of the Th2 response12. Additionally, in
a rabbit model of articular cartilage injury, Condrosulf under
pre-treatment regimenwas found to have a protective effect on the
damaged cartilage13. Finally, CS administration reduced the
concentration of the proinﬂammatory molecules C-reactive protein
(CRP) and IL-6 and the nuclear translocation of nuclear factor-kB in
a rabbit model of atherosclerosis aggravated by chronic arthritis14.
Rodent models of OA and rheumatoid arthritis (RA) are useful
tools to study these pathogenic processes. Adjuvant arthritis (AAR)
is one of the most widely used models. Rat AAR is an experimental
model of polyarthritis that has been widely used for the testing of
numerous antiarthritis agents either under preclinical or clinical
investigation, as well as being therapeutic in this disease15e17. The
hallmarks of thismodel are the reliable onset of robust polyarticular
inﬂammation, marked bone resorption, and periosteal bone prolif-
eration. Cartilage destruction occurs but it is disproportionally mild
in comparison to the inﬂammation and bone destruction that occur.
While no models mimic perfectly the condition of human diseases,
theyare easily reproducible,well deﬁned andhave proven useful for
the development of new therapies for arthritis, as exempliﬁed by
cytokine blockade therapies. Furthermore, AAR has been exten-
sivelyused for pharmaceutical testing, and thereforemoredata exist
for comparison in humans15e17. Due to these features, in this study
we report the effect of two different doses of CS in the AAR animal
model after oral administration under both pre-treatment and
treatment regimens.
Experimentals
The study drug, highly pure CS, Condrosulf, was provided by
Institut Biochimique S.A. (IBSA, CH-6915 Pambio Noranco, Lugano,
Svizzera). The structural characterization of CS and determination of
the disaccharide composition along with its main characteristics,
such as charge density, 4-sulfated/6-sulfated ratio, and molecular
mass parameters, were performed as previously reported in detail2,3.
Animals, experimental design and treatments
Male Lewis rats, weighing 160e180 g, were obtained from the
Dobra Voda Breeding Farm (Slovakia). The rats had free access to
a standard pelleted diet and tap water. The animal facilities comply
with the European Convention for the Protection of Vertebrate
Animals Used for Experimental and Other Purposes. The experi-
mental protocol was approved by the Ethics Committee of the
Institute of Experimental Pharmacology and Toxicology and by the
Slovak State Veterinary Committee of Animal Experimentation. AAR
was induced by a single intradermal injection of heat-inactivated
Mycobacterium butyricum (MB) in incomplete Freund’s adjuvant
(Difco Laboratories, Detroit, MI, USA). The injection was performed
near the tail base. The experiments included healthy animals (HC),
untreated arthritic animals (AA), AA having been administered
300 mg/kg b.w. of CS daily, using gastric gavage 14 days before AAR
induction (day 1) until the end of the experiment (day 28) (AA-CS-PT300), AA having been administered 900 mg/kg b.w. of CS daily,
using gastric gavage 14 days before AAR induction (day 1) until the
end of the experiment (day 28) (AA-CS-PT900), AA administered
300mg/kg b.w. of CS daily, using gastric gavage from day 1 until the
end of the experiment (day 28) (AA-CS-T300), and AA having been
administered 900 mg/kg b.w. of CS daily, using gastric gavage from
day 1 until the end of the experiment (day 28) (AA-CS-T900). In each
experimental group 10 animals were used. The duration of the
experiment was 42 days (14 þ 28) in the case of the pre-treatment
regimen and 28 days in the case of the treatment regimen. The basic
parameters were measured once each monitored experimental day
for each animal. The samples for biochemical and immunological
analysis were collected from each animal at the monitored experi-
mental days and measured in duplicate (two parallel assessments).
A graphical illustration of the experimental design is given on Fig. 1.
Blood collection
Blood was collected under light ketamin/xylasine anesthesia
(ketamineNarkamon 5% 50ml sol. inj. SPOFA, Czech Republic and
xylasine e Rometar 2% 50 ml sol. inj. SPOFA, Czech Republic) from
the retro-orbital plexus into lithium heparin (Sarstedt Multivette)
blood sample collectors on days 14 and 28 and ﬂow cytometric
measurements were immediately performed. After the animals had
been sacriﬁced under deep ketamin/xylasine anesthesia, blood for
plasma preparation and tissues for spleen and hind paw joint
homogenate preparationwere taken on day 28. Heparinized plasma
was stored at 70C until biochemical and immunological analyses
were performed.
Clinical parameters; hind paw volume (HPV), body weight of
animals and arthrogram
HPV increase was calculated as the percentage increase in the
HPV on a given experimental day in relation to the HPV at the
beginning of the experiment. The HPV was recorded on days 1, 14,
21, and 28with the use of an electronicwater plethysmometer (UGO
BASILE, Comerio-Varese, Italy). The body weight of the animals (g)
was measured on days 1, 14, 21 and 28. The arthrogram was
measured as the total score of HPV (ml, max. points 8) þ paw
diameter of forelimb (mm, max. points 5)þ diameter of scab, in the
site of MB application, measured parallel to the spinal column (mm,
max. points 5) for each animal.
Total antioxidant status (TAS)
Incubation of ABTS [2,20-azinobis(3-ethylbenzothiazoline-6-
sulfonate)] with peroxidase (metmyoglobin) results in the
production of the radical cation ABTSþ. This species is blue-green
Table I
Main structural parameters of CS, Condrosulf, used in this
study
Parameters Values
MWn 16,090
MWw 23,900
Dispersity Mw/Mn 1.485
Disaccharide 0S 8.6
Disaccharide 6S 34.8
Disaccharide 4S 56.6
Disaccharide 2S Trace
Disulfated disaccharides Trace
Charge density 0.91
4S/6S Ratio 1.63
CS Content %
Electrophoresis 99.0
Disaccharides 99.7
HPSEC 98.9
Mn, average molecular weight number. Mw, average molecular
weight. Disaccharide 0S, HexA-GalNAc. Disaccharide 6S,
HexA-GalNAc (6-OSO3). Disaccharide 4S, HexA-GalNAc
(4-OSO3). Disaccharide 2S, HexA (2-OSO3)-GalNAc. Charge
density is calculated as number of sulfate groups per disac-
charide unit. nd ¼ not detected.
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cause inhibition of this color production to a degree that is
proportional to their concentration. The plasma samples were
measured according to the manufacturer’s instructions (RANDOX
TAS kit) using a microplate reader (Labsystems Multiskan RC).
According toMiller et al.18 the TASmeasurement procedurewith
RANDOX TAS kit has been applied to physiological antioxidant
compounds and radical-scavenging drugs, and an antioxidant
ranking was established based on their reactivity relative to
a 1.0 mmol/L Trolox standard. The producer declares that RANDOX
TAS kit possesses a wide measuring range (0e2.5 mmol/l),
intra-assay C.V. of 1.2% and inter-assay C.V. of 2.4%.
Tissue activity of cellular g-glutamyltransferase (GGT)
The activity of cellular GGT in hind paw joint tissue homoge-
nates was measured by the method of Orlowski and Meister19 as
modiﬁed by Ondrejickova et al.20 The samples were homogenized
in a buffer (2.6 mM NaH2PO4, 50 mM Na2HPO4, 15 mM EDTA,
68 mM NaCl; pH 8.1) at 1:9 (w/v) by UltraTurax TP 18/10 (Janke &
Kunkel, Germany) for 1 min at 0C. Substrates (8.7 mM g-glutamyl-
p-nitroanilide, 44 mM methionine) were added to 65% iso-
propylalcohol in ﬁnal concentrations of 2.5 mM and 12.6 mM,
respectively. After incubation for 60 min at 37C, the reaction was
stopped with 2.3 ml cold methanol and the tubes were centrifuged
for 20 min at 5000 rpm. The absorbance of the supernatant was
measured in a Specord 40 (Jena, Germany) spectrophotometer in
a 0.5 cm cuvette at 406 nm. Reaction mixtures in the absence of
either substrate or acceptor were used as reference samples.
Measurement of pro-inﬂammatory cytokines IL-1b and IL-6
For the determination of IL-1 and IL-6 concentration in plasma,
the ELISA kit from R&D Systems Quantikine was used. Assay
procedures were used as described in the product manual. Rat
cytokine present in the samples binds to anti-rat cytokine anti-
bodies absorbed in the microwells. The reaction of secondary
biotin-conjugated anti-rat cytokine antibody is evaluated by
Streptavidin-horseradish peroxidase (HRP). The tetramethyl-
benzidine reaction with HRP bound to immune complex was
measured at 490 nm in comparison with the reference wavelength
620 nm (microplate reader MRX II, DYNEX, USA). The results were
calculated using the standard calibration curve on internal
standards.
CRP
For the determination of rat CRP concentration in plasma the
ELISA kit from Immunology Consultant Laboratories, Inc. (ICL) was
used. The reaction of secondary biotin-conjugated anti-rat CRP
antibody is evaluated by streptavidin-HRP. The tetramethyl-
benzidine reaction with HRP bound to immune complex was
measured at 450 nm (microplate reader Labsystems Multiskan RC).
The results were calculated using the standard calibration curve on
internal standards.
Immunocytometric evaluation of simultaneous phagocytosis and
oxidative burst
A slightmodiﬁcation of themethod of Kronek et al.21 was used for
the whole rat blood and applied as follows. Phagocytosis accompa-
nied by the respiratory burst of rat neutrophils was evaluated by ﬂow
cytometry (Beckman-Coulter FC 500 ﬂow cytometer running under
CXP software). For each blood sample, the ﬂuorescence histogram of
5000 cells was generated and analyzed. Gates were set aroundgranulocytes to exclude debris. Measurements of phagocytosis, i.e.,
ingestion of bacteria, took place under controlled conditions using
a ﬂuorescein labeled opsonized Staphylococcus aureus (SPA-FITC)
(Invitrogen Molecular Probes, USA). Aliquots of peripheral blood in
lithium-heparin were incubated with hydroxyethidine (Invitrogen
Molecular Probes, USA) (15.75 mg in 5 mL of dimethylformamide,
Merck, Germany) for 15 min at 37C. Following treatment with SPA-
FITC for the next 15 min at 37C, the reaction was stopped with ice.
The subsequent erythrocyte lysis was performed for 15 min with an
ice-cold ammoniumechlorideepotassium chloride lysis buffer
(200 mL deionized water, 1.658 g NH4Cl, 0.2 g KHCO3, 7.4 mg
Na2EDTA, pH 7.2e7.4). The mean percentage of phagocytic cells
represents the percentage of granulocytes ingesting at least one SPA-
FITC particle and themeanpercentage of respiratory burst represents
the percentage of granulocytes tagged by ethidium.
Statistical analysis
The data were expressed in terms of arithmetic mean with 95%
conﬁdence interval (CI). The untreated arthritis group was
comparedwith healthy control animals, the treated arthritis groups
were comparedwith the untreated OA. For signiﬁcance calculations
the Student’s t test (two samples, unequal variance) was used.
P > 0.05 was considered not signiﬁcant.
Results
Characterization of the structure and properties of CS drug
Table I summarizes the disaccharide composition of CS, Con-
drosulf, used in the study and its main characteristics, such as
charge density, 4-sulfated/6-sulfated ratio, and molecular mass.
Furthermore, CS from Condrosulf is a highly puriﬁed drug (over
99%) as determined by several analytical approaches, such as
electrophoresis, HPLC of disaccharides, and high-performance size-
exclusion chromatography (HPSEC) (Table I).
Basic parameters
HPV was found to strongly increase in animals treated from day
1 and pre-treatment with a higher CS dose (900 mg/kg) signiﬁ-
cantly decreased HPV throughout the whole experiment (up
Table II
HPV values evaluated at different days during pre-treatment (PT) and treatment (T) with two CS doses of 300 and 900 mg/kg. AA, untreated arthritic animals. AA-CS-PT300,
AA having been administered 300 mg/kg b.w. of CS daily, using gastric gavage 14 days before AAR induction (day 1) until the end of the experiment (day 28). AA-CS-PT900, AA
having been administered 900 mg/kg b.w. of CS daily, using gastric gavage 14 days before AAR induction (day 1) until the end of the experiment (day 28). AA-CS-T300, AA
administered 300mg/kg b.w. of CS daily, using gastric gavage from day 1 until the end of the experiment (day 28). AA-CS-T900, AA having been administered 900mg/kg b.w. of
CS daily, using gastric gavage from day 1 until the end of the experiment (day 28). The data are expressed in terms of mean, % of differences vs HC or AA, and arithmetic mean
with 95% CI. P > 0.05 was considered not signiﬁcant. Signiﬁcant differences are reported in bold
HPV
Day 14 Day 21 Day 28
Mean vs HC vs AA P LL UL Mean vs HC vs AA P LL UL Mean vs HC vs AA P LL UL
HC 10.1 8.00 12.20 15.4 12.38 18.42 20.90 16.94 24.86
AA 55.9 453% 6.5e-6 42.88 68.92 98.9 541% 2.6e-7 84.14 113.66 86.80 315% 1.4e-6 71.93 101.67
AA-CS-PT300 38.4 31% 0.019 26.82 49.98 88.5 11% 0.158 78.29 98.71 83.20 4% 0.724 62.02 104.38
AA-CS-PT900 20.9 63% 3.0e-5 12.79 29.01 70.6 29% 0.0013 59.61 81.59 65.90 24% 0.0169 52.18 79.62
AA-CS-T300 49.0 12% 0.336 36.62 61.38 98.6 0% 0.973 83.42 113.78 92.40 6% 0.4970 78.28 106.52
AA-CS-T900 55.8 0% 0.999 41.30 70.30 75.9 23% 0.0080 63.07 88.73 69.70 20% 0.0367 57.40 82.00
LL: Lower limit.
UL: Upper limit.
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decreased HPV on days 21 and 28 byw20e23% (Table II).
After 28 days of treatment, body weight was found decreased of
w30% in AA (P < 1.46e-10, CI 95% 189.8O 209.0 vs 271.5O 295.9
of controls). Pretreatment with 300 mg/kg CS was able to restore
body weight of w8% (P < 0.0035, CI 95% 208.5 O 222.6) and
pretreatment with 900 mg/kg produced an increase of w13%
(P < 0.00007, CI 95% 217.0O 234.7). No signiﬁcant modiﬁcations of
body weight were observed after CS treatment with both doses.
The severity of arthritis was quantiﬁed by scoring the front paw
from 1 to 5 and the hind paw from 1 to 8, based on increasing levels
of swelling and periarticular erythema. Also the scab at the base of
the rat’s tail was scored from 1 to 5 according to its diameter. The
sum of the scores for the limbs and scab was calculated as the
arthritic score, with a maximum possible score of 31 per rat. The
complete arthritic score is illustrated in Table III. As appears
evident, the higher dose of CS (900 mg/kg) administered both as
pre-treatment and treatment was signiﬁcantly effective in
decreasing the arthritic score. Furthermore, pre-treatment was
effective throughout the whole subacute phase (from day 14 to 28,
up to 17%), while treatment was only effective on days 21e28 (up
to 9%) (Table III).
Biochemical parameters
Oxidative stress, a consequence of the chronic inﬂammatory
processes occurring in AAR, increased on both experimental days 14
and 28, with a somewhat higher value on day 14 when also clinical
manifestations of the disease started. Oxidative stress increased theTable III
Arthritic score evaluated at different days during pre-treatment (PT) and treatment (T) wi
AA having been administered 300 mg/kg b.w. of CS daily, using gastric gavage 14 days befo
having been administered 900 mg/kg b.w. of CS daily, using gastric gavage 14 days befo
administered 300mg/kg b.w. of CS daily, using gastric gavage from day 1 until the end of th
CS daily, using gastric gavage from day 1 until the end of the experiment (day 28). The da
95% CI. P > 0.05 was considered not signiﬁcant. Signiﬁcant differences are reported in b
A
Day 14 Day 21
Mean vs AA P LL UL Mean vs AA
AA 17.6 16.21 18.99 22.9
AA-CS-PT300 16.6 6% 0.2321 15.06 18.14 23.0 0%
AA-CS-PT900 14.6 17% 0.0009 13.26 15.94 20.8 9%
AA-CS-T300 17.4 0% 0.8330 15.44 19.36 23.8 4%
AA-CS-T900 17.5 0% 0.9010 16.00 19.00 20.5 9%
LL: Lower limit.
UL: Upper limit.consumption of endogenous antioxidants in plasma and thus
caused a lowering of the plasma antioxidant capacity, measured as
the TAS. Only pre-treatment with CS was effective in correcting the
TAS in AAR, asmeasured on day 14 (Table IV). This ﬁnding correlates
well with the changes in the weight of the animals.
The activity of GGT was measured in the tissue homogenates of
the joint on experimental day 28. GGT activity markedly increased
in AAR animals (Table IV). GGT activity was decreased in animals
treated with the higher dose of CS (CS-PT-900, CS-T-900) in
comparison with the untreated AAR animals. This is in good
agreement with the changes in HPV (see Table II).
Immunological parameters
IL-1b and IL-6 are keypro-inﬂammatorycytokines. Both cytokines
were signiﬁcantly increased in AAR on both days monitored, with
a dramatic increase of IL-6 on day 14, more than 10-fold in compar-
ison to the healthy controls (Table V). The therapeutic effect of CSwas
manifest on day 14 particularly in the case of the pre-treatment
groups (CS-PT-300, CS-PT-900). As for IL-1b, the increased plas-
matic concentrations were maintained on day 28 at about the same
level as on day 14. A beneﬁcial effect of CS on IL-1b concentrationwas
achieved on day 28 after administration of both drug doses given as
pre-treatment (CS-PT-300, CS-PT-900) and also after administration
of the higher dose of CS given as treatment (CS-T-900) (Table V).
With regard to the plasmatic levels inAAR, the basic inﬂammatory
protein marker, CRP, has a very similar time proﬁle to IL-6 (Table V).
The increase on day 14 wasw7.5-fold for AAR in comparison to the
controls. Similarly to IL-6, the effect of CS on the CRP level was notth two CS doses of 300 and 900mg/kg. AA, untreated arthritic animals. AA-CS-PT300,
re AAR induction (day 1) until the end of the experiment (day 28). AA-CS-PT900, AA
re AAR induction (day 1) until the end of the experiment (day 28). AA-CS-T300, AA
e experiment (day 28). AA-CS-T900, AA having been administered 900mg/kg b.w. of
ta are expressed in terms of mean, % of differences vs AA, and arithmetic mean with
old
rthritic score
Day 28
P LL UL Mean vs AA P LL UL
20.39 25.41 22.9 21.11 24.69
0.9330 20.83 25.17 23.4 2% 0.7063 20.70 26.10
0.1179 18.74 22.86 21.5 5% 0.2347 19.23 23.77
0.7613 21.09 26.51 23.8 4% 0.4399 21.54 26.06
0.0399 18.78 22.22 21.3 7% 0.0440 19.46 23.14
Table IV
TAS on day 14 and GGT activity measured in tissue homogenates of joint on experimental day 28. AA, untreated arthritic animals. AA-CS-PT300, AA having been administered
300 mg/kg b.w. of CS daily, using gastric gavage 14 days before AAR induction (day 1) until the end of the experiment (day 28). AA-CS-PT900, AA having been administered
900mg/kg b.w. of CS daily, using gastric gavage 14 days before AAR induction (day 1) until the end of the experiment (day 28). AA-CS-T300, AA administered 300mg/kg b.w. of
CS daily, using gastric gavage from day 1 until the end of the experiment (day 28). AA-CS-T900, AA having been administered 900 mg/kg b.w. of CS daily, using gastric gavage
from day 1 until the end of the experiment (day 28). The data are expressed in terms of mean, % of differences vs HC or AA, and arithmetic mean with 95% CI. P > 0.05 was
considered not signiﬁcant. Signiﬁcant differences are reported in bold
TAS GGT activity in joint
Mean vs HC vs AA P LL UL Mean vs HC vs AA P LL UL
HC 0.63 0.41 0.85 17.9 14.30 21.50
AA 0.25 70% 0.0002 0.13 0.37 35.5 98% 0.0000 28.43 42.57
AA-CS-PT300 0.39 56% 0.0037 0.31 0.47 37.1 4% 0.2200 29.31 44.89
AA-CS-PT900 0.34 36% 0.0320 0.26 0.42 28.4 20% 0.0000 24.11 32.69
AA-CS-T300 0.28 12% 0.5340 0.18 0.37 33.2 6% 0.0003 27.60 38.80
AA-CS-T900 0.20 20% 0.2040 0.15 0.25 28.8 19% 0.0133 22.04 35.56
LL: Lower limit.
UL: Upper limit.
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concentration in plasma was achieved due to the higher dose of CS
administered as pre-treatment (CS-PT-900) and a slight improve-
ment was also observed due to both doses of CS administered under
the treatment regimen (CS-T-300, CS-T-900) (Table V).
Functionality of neutrophils
For phagocytic activity and the intracellular oxidative burst of
neutrophil functionality, the differences observed between the
control and AAR groups were signiﬁcant, with the exception of the
oxidative burst measured on day 28. AAR caused an enhancement
of both parameters (Table V). On day 14, the administration of CS
under the pre-treatment regimen induced a lowering of phagocy-
tosis and oxidative burst (Table V). The differences observed on day
28 were minor (not shown).Discussion
Injection of rats with complete or incomplete adjuvant induces
polyarthritis, possibly by way of a mechanism involving heatTable V
IL-1b values on day 28, IL-6 levels on day 14, plasmatic levels of CRP determined on d
administration of CS in the pre-treatment and treatment regimens. AA, untreated arthrit
using gastric gavage 14 days before AAR induction (day 1) until the end of the experimen
using gastric gavage 14 days before AAR induction (day 1) until the end of the experime
gavage from day 1 until the end of the experiment (day 28). AA-CS-T900, AA having been a
of the experiment (day 28). The data are expressed in terms of mean, % of differences vs H
Signiﬁcant differences are reported in bold
IL-1b IL-6
Mean vs HC vs AA P LL UL Mean vs HC vs AA
HC 10.0 6.61 13.39 14.7
AA 23.3 133% 0.001 17.90 28.70 245.6 1571%
AA-CS-PT300 15.1 35% 0.0017 10.14 20.06 146.8 40%
AA-CS-PT900 15.0 36% 0.022 9.14 20.86 171.2 30%
AA-CS-T300 18.5 21% 0.099 14.52 22.48 260.6 6%
AA-CS-T900 13.4 42% 0.0066 8.44 18.36 214.8 12%
Phagocytic activity of neutrophils
Mean vs HC vs AA P LL U
HC 61.8 52.55 7
AA 74.4 20% 0.0012 66.43 8
AA-CS-PT300 59.0 21% 0.0018 54.89 6
AA-CS-PT900 59.6 20% 0.0023 55.75 6
AA-CS-T300 76.6 3% 0.3868 71.97 8
AA-CS-T900 82.7 11% 0.3950 80.13 8
LL: Lower limit.
UL: Upper limit.shock proteins22. This model is termed as the AAR model, and has
been used to test new drugs for inﬂammatory arthritis. AAR has
been used in the evaluation of nonsteroidal inﬂammatory drugs
such as phenylbutazone and aspirin during the early 1960s, and
later COX-2 inhibitors such as celecoxib22. AAR in rats shares
many features with human arthritis including genetic linkage,
synovial CD4þ cells and T cell dependence22. On the contrary, one
of the major differences between the AAR model and human
arthritis is simply that the inciting agent is known in the model,
though the need for any speciﬁc antigen is controversial. In this
model, the joint inﬂammation progresses from an initial acute
phase (1e5 days) through a remission phase (day 10), followed by
a spontaneous reactivation phase. The reactivation phase starts
around day 14 (subacute phase) and the joint swelling progres-
sively increases and becomes chronic within 4 weeks and persists
for months22.
CS in its highly pure composition is capable of signiﬁcantly
reducing the severity of arthritis along with the oxidative stress,
a consequence of the chronic inﬂammatory processes occurring in
AAR. CS at a dose of 900 mg/kg was signiﬁcantly effective in
decreasing the arthritic score administered both as pre-treatment
and treatment. It is worth mentioning that the CS pre-treatmentay 14, phagocytic activity and oxidative burst of neutrophils on day 14 during the
ic animals. AA-CS-PT300, AA having been administered 300 mg/kg b.w. of CS daily,
t (day 28). AA-CS-PT900, AA having been administered 900 mg/kg b.w. of CS daily,
nt (day 28). AA-CS-T300, AA administered 300 mg/kg b.w. of CS daily, using gastric
dministered 900mg/kg b.w. of CS daily, using gastric gavage from day 1 until the end
C or AA, and arithmetic mean with 95% CI. P > 0.05 was considered not signiﬁcant.
CRP
P LL UL Mean vs HC vs AA P LL UL
7.50 21.90 356.5 168.12 544.88
0.0019 132.78 358.42 2821.7 692% 0.0079 1326.47 4316.93
0.0370 73.30 220.30 2368.3 16% 0.5710 854.31 3882.29
0.0460 110.03 232.37 1008.3 64% 0.0250 573.97 1442.63
0.8180 142.64 378.56 1586.9 44% 0.095 875.52 2298.28
0.5640 143.87 285.73 1712.4 39% 0.1620 577.23 2847.57
Oxidative burst of neutrophils
L Mean vs HC vs AA P LL UL
1.05 44.2 37.52 50.88
2.37 61.0 38% 0.0007 53.29 68.71
3.11 36.1 41% 0.0000 33.27 38.93
3.46 37.4 39% 0.0000 33.55 41.26
1.23 66.2 8% 0.1278 60.55 71.85
5.27 17.0 11% 0.1100 12.12 21.88
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day 14 to 28, up to63%) while CS treatment was effective only on
days 21e28 at the onset of the chronic period. These aspects were
conﬁrmed by correcting the TAS in which pre-treatment with CS
was effective throughout the subacute phase, and by GGT activity,
which was decreased in animals treated with the higher dose of
CS. Furthermore, we assume that the increased activity of GGT in
AAR is a result of elevated systemic oxidative stress. GGT acts as
a bone-resorbing factor that stimulates osteoclast formation. GGT
expression has been detected in active lymphocytes that accu-
mulate at the inﬂammation region, as in RA. Ishizuka et al.23 found
that neutralizing antibodies against GGT had therapeutic effect on
joint destruction in a collagen-induced arthritis in mice. Elevated
expression and activity of GGT in joint tissue is a good marker for
synovial inﬂammation and bone resorption, thus molecules able
to reduce the activity and/or expression of GGTcould be important
for RA therapy.
Animal models provide insight into the role of soluble factors in
arthritis (and also in RA) as not all cellular interactions are carried
out by direct cell-to-cell contact. Pro-inﬂammatory cytokines, such
as IL-1b and IL-6, regulate inﬂammatory and immune responses
and play a pivotal role in steering the disease in arthritis models.
Time course studies have consistently found IL-1b and IL-6 (and
other key pro-inﬂammatory cytokines and chemokines) expressed
in a variety of autoimmune disease models including AAR22. In
particular, IL-1b promotes cartilage and bone destruction, whereas
IL-6 is produced by a multitude of cell types capable of stimulating
the inﬂammatory response. This knowledge has led to current trials
of anti-IL-6 therapy in RA22. CS administered under a pre-treatment
regimen was signiﬁcantly able to reduce the production of these
pro-inﬂammatory cytokines throughout the whole subacute phase
(from day 14 to 28), while CS administered as treatment at the
higher dose was also able to decrease arthritic cytokines at the
onset of the chronic period. According to its capacity to reduce pro-
inﬂammatory cytokines, CS was also able to signiﬁcantly decrease
CRP concentration in plasma, particularly when administered as
pre-treatment.
Neutrophils are considered to be important in models of
inﬂammation since they have the potential to play a two-fold role,
ﬁrst in the initial response and later in the destructive process of
the chronic phase24. In our animal model, AAR triggered a marked
enhancement of phagocytic activity and the intracellular oxidative
burst of neutrophil functionality. CS under the pre-treatment
regimen was able to decrease both parameters, particularly
during the subacute phase.
RA is a multisystem disease with underlying immune mech-
anisms. OA is a debilitating, progressive disease of the dia-
rthrodial joints associated with the aging process. Althoughmuch
is known about the pathogenesis of RA and OA, our under-
standing of some immunological changes remains incomplete.
However, several studies have focused their attention on the
possibility that the cytokine levels in RA and OA correlate posi-
tively with some common clinicopathological features25. In fact,
the development of RA and OA is associated with the common
alteration of the plasmatic levels of some cytokines, such as Il-1b
and IL-6 (along with TNF-a)25. Furthermore, the AAR animal
model shows several common features of OA and RA24. As
a consequence, CS pre-treatment and/or treatment may be useful
to reduce inﬂammatory mediators and processes not only in OA,
as documented by many clinical trials and meta-analysis stud-
ies4,7,8,26e28, but also in RA.
It is likely that inﬂammatory arthritis events are triggered by
the activation of Toll-like receptors (TLRs), either at the secondary
lymphoid organs or at the arthritis synovium, since TLRs are
known to mediate the activation of NF-kB and MAPKs resulting inthe production of pro-inﬂammatory cytokines. A critical mediator
of intracellular TLR signaling is the transcription factor NF-kB,
which regulates the production of various cytokines, adhesion
molecules and antiapoptotic factors29,30. Several in vitro
studies31,32 have focused on the possibility that CS may reduce
inﬂammation processes by acting on the nuclear translocation of
NF-kB, associated with blood biomarkers of inﬂammation,
primarily IL-1, IL-6 and CRP. In this study, we demonstrated
a sharp decrease in thesemarkers in our animalmodel, conﬁrming
in vivo the potential of CS to regulate NF-kB activity. Overall, on the
basis of this evidence, CS proved to have a beneﬁcial effect in
slowing down AAR development and in reducing disease markers,
which is indicative of its beneﬁcial activity in humans as a drug. Its
therapeutic potential should be evaluated not only in the treat-
ment of OA but also of RA, due to its protective effect on joint
structural changes as documented in a randomized, double-blind,
placebo-controlled pilot study using magnetic resonance imaging
(MRI)33. The effect of CS on subchondral bone and synovium
inﬂammation should be further studied as recommended also by
Henrotin et al.34
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